

J-1891  
PTO

98-27-01  
Box 509

Please type a plus sign (+) inside this box → +

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. §1.53(b))

Approved for use through 09/30/2000 OMB 0651-0032  
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Attorney Docket No.	PC10761A	
First Named Inventor or Application Identifier		Morsey, et al.
Title	ANTI-IgE VACCINES	
Express Mail Label No.	EL639818052US	

<b>APPLICATION ELEMENTS</b> See MPEP chapter 600 concerning utility patent application contents.		<b>ADDRESS TO:</b> Assistant Commissioner for Patents Box Patent Application Washington, DC 20231	
1. <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original, and a duplicate for fee processing)</i>		6. <input checked="" type="checkbox"/> Microfiche Computer Program (Appendix)	
2. <input checked="" type="checkbox"/> Specification [Total Pages 44]		7. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i>	
- Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R&D - Reference in Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings ( <i>if filed</i> ) - Detailed Description - Claim(s) - Abstract of the Disclosure		a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies	
3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 11.3) [Total sheets 5]		<b>ACCOMPANYING APPLICATION PARTS</b>	
4. <input type="checkbox"/> Oath or Declaration [Total pages 1]		8. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))	
a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR §1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i> <b>[Note Box 5 below]</b>		9. <input type="checkbox"/> 37 C.F.R. § 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i>	
i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b).		10. <input type="checkbox"/> English Translation Document ( <i>if applicable</i> )	
5. <input type="checkbox"/> Incorporation By Reference ( <i>useable if Box 4b is checked</i> ) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.		11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations	
		12. <input checked="" type="checkbox"/> Preliminary Amendment	
		13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i>	
		14. <input type="checkbox"/> Small Entity <input type="checkbox"/> Statement filed in prior application, Statement(s) ( <i>PTO/SB/09-12</i> ) <input type="checkbox"/> Status still proper and desired	
		15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>	
		16. <input checked="" type="checkbox"/> Other: Priority Claimed from United States Provisional Patent Application 60/228,989, filed August 30, 2001.	
<b>"NOTE FOR ITEMS 1 &amp; 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28)."</b>			
17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP)    of prior application No: / _____			
Prior application information: Examiner _____		Group/Art Unit: _____	

<b>18. CORRESPONDENCE ADDRESS</b> (Insert Customer No. or Attach bar code label here) or <input checked="" type="checkbox"/> Correspondence address below					
<input type="checkbox"/> Customer Number or Bar Code Label					
Name	Paul H. Ginsburg				
Address	Pfizer Inc				
Address	235 East 42nd Street, 20th Floor				
City	New York	State	New York	Zip Code	10017-5755
Country	United States Of America	Telephone	(212)573-2369		Fax (212)573-1939
NAME (Print/type)	Lorraine B. Ling		Registration No. (Attorney/Agent)	35,251	
Signature	<i>Lorraine B. Ling</i>		Date	August 24, 2001	

**EXPRESS MAIL NO. EL639818052US**

UTILITY TRANSMITTAL PTO SB 05, 3/99, (1/1)

## FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.  
These are the fees effective October 1, 1997.

**Small Entity payments must be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12.**

See 37 C.F.R. §§ 1.27 and 1.28.

Total Amount of Payment (\$2,798.00)

<b>Complete If Known</b>	
Application Number	Not Yet Assigned
Filing Date	Herewith
First Named Inventor	Morse, et al.
Examiner Name	Not Yet Assigned
Group/Art Unit	Not Yet Assigned
Attorney Docket No.	PC10761A

### METHOD OF PAYMENT (check one)

The commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 16-1445

Deposit Account Name

Charge Any Additional Fee Required Under 37 C.F.R. §§ 1.16 and 1.17       Charge the Issue Fee Set in 37 C.F.R. § 118 at the Mailing of the Notice of Allowance

Payment Enclosed:

Check     Money Order     Other

### FEE CALCULATION (continued)

3. ADDITIONAL FEES		Fee Description				Fee Paid
Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Code	Fee (\$)	
		105	130	205	65	Surcharge - late fee or oath
		127	50	227	25	Surcharge - late provisional filing fee or cover sheet
		139	130	139	130	Non-English specification
		147	2,520	147	2,520	For filing a request for reexamination
		112	920*	112	920*	Requesting publication of SIR prior to Examiner action
		113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action
		115	110	215	55	Extension for reply within first month
		116	390	216	195	Extension for reply within second month
		117	890	217	445	Extension for reply within third month
		118	1,390	218	695	Extension for reply within fourth month
		128	1,890	228	945	Extension for reply within fifth month
		119	310	219	155	Notice of Appeal
		120	310	220	155	Filing a brief in support of an appeal
		121	270	221	135	Request for oral hearing
		138	1,510	138	1,510	Petition to institute a public use proceeding
		140	110	240	55	Petition to revive - unallowable
		141	1,240	241	620	Petition to revive - unintentional
		142	1,240	242	620	Utility issue fee (or reissue)
Total Claims	41	-20**=	21	X	18	= 378
Independent Claims	21	- 3**=	18	X	80	= 1,440.00
Multiple Dependent			270	=	270.00	
<b>SUBTOTAL (1) (\$)</b>		<b>710</b>				
<b>2. EXTRA CLAIM FEES</b>						
		Extra Claims	Fee from below	Fee Paid		
Total Claims	41	-20**=	21	X	18	= 378
Independent Claims	21	- 3**=	18	X	80	= 1,440.00
Multiple Dependent			270	=	270.00	
** or number previously paid, if greater. For Reissues, see below						
Large Entity	Small Entity					
Fee Code (\$)	Fee Code (\$)	Fee (\$)	Fee (\$)	Fee Description		
103	18	203	9	Claims in excess of 20		
102	80		40	Independent claims in excess of 3		
104	270	204	135	Multiple dependent claim, if not paid		
109	80	209	40	**Reissue independent claims over original patent		
110	18	210	9	**Reissue claims in excess of 20 and over original patent		
<b>SUBTOTAL (2) (\$)</b>		<b>2,088.00</b>				
*Reduced by Basic Filing Fee Paid						
						<b>SUBTOTAL (3) (\$)</b>

### SUBMITTED BY

Type or Printed Name Lorraine B. Ling

Signature *Lorraine B. Ling*

Date August 24, 2001

Complete (if Applicable)

Reg. Num. 35,261

Deposit Account

User ID

**EXPRESS MAIL NO. ELL639818052US**

FEETRANSMIITAL PTO SB 17.DOT

Patent Application  
Attorney Docket No. PC10761A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

**MORSEY, ET AL.**

APPLICATION NO.: **Not Yet Assigned**

Examiner: **Not Yet Assigned**

Group Art Unit: **Not Yet  
Assigned**

FILING DATE: **Herewith**

TITLE: **ANTI-IgE VACCINES**

Commissioner for Patents  
Washington, D.C. 20231


Sir:

STATEMENT UNDER 37 CFR 1.821

I hereby state that the information recorded in computer readable form is the same as the written sequence listing.

Respectfully submitted,

Date: August 24, 2001

  
Lorraine B. Ling  
Attorney for Applicant(s)  
Reg. No. 35,251

Pfizer Inc  
Patent Department, 5th Fl.  
150 East 42nd Street  
New York, NY 10017-5612  
(212) 573-2030

EXPRESS MAIL NO.: EL639818052US